Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes

International Journal of Clinical Practice

Volumn 69, Issue 11, 2015, Pages 1221-1235

  Saulsberry, W J ^a   Coleman, C I ^a   Mearns, E S ^a   Zaccaro, E ^a   Doleh, Y ^a   Sobieraj, D M ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; TASPOGLUTIDE;

ADD ON THERAPY; ARTICLE; COMPARATIVE EFFECTIVENESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; GENITAL TRACT INFECTION; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; META ANALYSIS;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES;

EID: 84946497765     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12698     Document Type: Article

References (30)

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW,. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al.,; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes, 2015: a patient centered approach: update to a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2015; 38: 140-149.
3. Phung OJ, Scholle JM, Talwar M, Coleman CI,. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-1418.
4. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al.,; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 18 (343): d5928.
5. Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org. (accessed June 27, 2014).
6. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
7. Sterne JAC, Gavaghan D, Egger M,. Publication and related bias in meta-analysis: power of statistical tests and prevalence in literature. J Clin Epidemiol 2000; 53: 1119-1129.
8. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al., Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011; 14: 429-437.
9. Package 'netmeta'. June 24, 2014. http://cran.rproject.org/web/packages/netmeta/netmeta.pdf (accessed June 27, 2014).
10. Rücker G,. Network meta-analysis, electrical networks and graph theory. Research Synthesis Methods 2012; 3: 312-324.
11. Krahn U, Binder H, König J,. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol 2103: 13; 35.
12. Fonseca V, Staels B, Morgan JD 2nd, Shentu Y, Golm GT, Johnson-Levonas AO, et al., Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. J Diabetes Complications 2013; 27: 177-83.
13. Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R, et al.,; T-Emerge 2 Study Group. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-Emerge 2 trial. Diabetes Care 2013; 36: 498-504.
14. Henry RR, Mudaliar S, Kanitra L, Woloschak M, Balena R,; T-Emerge 3 Study Group. Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial. J Clin Endocrinol Metab 2012; 97: 2370-9.
15. Roberts VL, Stewart J, Issa M, Lake B, Melis R,. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005; 27: 1535-47.
16. Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Piccinni MN, et al., A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy. Diabet Med 2013; 30: 846-54.
17. Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, et al., Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014; 37: 2159-67.
18. Bajaj M, Gilman R, Patel S, et al., Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. Diabet Med 2014; 31: 1505-14.
19. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, et al.,; on behalf of the EMPA-REG PIO™ Trial Investigators. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014; 16: 147-58.
20. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al.,; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-30.
21. Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, et al., Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014; 16: 467-77.
22. Dobs AS, Goldstein BJ, Aschner P, Horton ES, Umpierrez GE, Duran L, et al., Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. J Diabetes 2013; 5: 68-79.
23. Treadwell JR, Uhl S, Tipton K, Shamliyan T, Viswanathan M, Berkman ND, et al., Assessing equivalence and noninferiority. J Clin Epidemiol 2012; 65: 1144-9.
24. Lee YS, Jun HS,. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism 2014; 63:9, Demuth HU, McIntosh CH, Pederson RA. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005; 1751: 33.
25. Phung OJ, Scholle JM, Talwar M, Coleman CI,. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-1418.
26. Proks P, Reimann F, Green N, Gribble F, Ashcroft F,. Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51 (Suppl. 3): S368-76.
27. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, et al., Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669-72.
28. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, et al., GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013; 19: 567-575.
29. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB,. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8, 262-75.e9.
30. Scholes D, Hooton TM, Roberts PL, Gupta K, Stapleton AE, Stamm WE,. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med 2005; 142: 20-7.